Are we ready to downregulate mast cells?

Laila Karra; Beata Berent-Maoz; Micha Ben-Zimra; Francesca Levi-Schaffer

doi:10.1016/j.coi.2009.09.010

Are we ready to downregulate mast cells?

Laila Karra^*, Beata Berent-Maoz, Micha Ben-Zimra, Francesca Levi-Schaffer

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

51 Scopus citations

Abstract

Downregulation of mast cells (MCs) function and/or survival is warranted in allergic inflammation (AI), mastocytosis/MC leukemias and in other inflammatory diseases in which MCs have a central role. Human MCs (hMCs) have been recently shown to express the death receptor (DR) TRAIL and the inhibitory receptors (IRs) CD300a and Siglec-8. TRAIL is the only known DR functional on hMCs, and interestingly its function is upregulated by IgE-dependent MC activation. The newly described IRs, CD300a and Siglec-8, potently downregulate MC activation and survival in vitro and inhibit different IgE-mediated responses in vivo. Therefore a selective targeting of TRAIL and of IRs on MC could be a novel immunopharmacological way to downregulate MC-associated diseases.

Original language	American English
Pages (from-to)	708-714
Number of pages	7
Journal	Current Opinion in Immunology
Volume	21
Issue number	6
DOIs	https://doi.org/10.1016/j.coi.2009.09.010
State	Published - Dec 2009

Bibliographical note

Funding Information:
F Levi-Schaffer's research is supported by the Aimwell Charitable Trust (UK) and the Israeli Ministry of Health.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.coi.2009.09.010

Cite this

@article{bf790c25ef944a8b94a800c497965894,

title = "Are we ready to downregulate mast cells?",

abstract = "Downregulation of mast cells (MCs) function and/or survival is warranted in allergic inflammation (AI), mastocytosis/MC leukemias and in other inflammatory diseases in which MCs have a central role. Human MCs (hMCs) have been recently shown to express the death receptor (DR) TRAIL and the inhibitory receptors (IRs) CD300a and Siglec-8. TRAIL is the only known DR functional on hMCs, and interestingly its function is upregulated by IgE-dependent MC activation. The newly described IRs, CD300a and Siglec-8, potently downregulate MC activation and survival in vitro and inhibit different IgE-mediated responses in vivo. Therefore a selective targeting of TRAIL and of IRs on MC could be a novel immunopharmacological way to downregulate MC-associated diseases.",

author = "Laila Karra and Beata Berent-Maoz and Micha Ben-Zimra and Francesca Levi-Schaffer",

note = "Funding Information: F Levi-Schaffer's research is supported by the Aimwell Charitable Trust (UK) and the Israeli Ministry of Health.",

year = "2009",

month = dec,

doi = "10.1016/j.coi.2009.09.010",

language = "American English",

volume = "21",

pages = "708--714",

journal = "Current Opinion in Immunology",

issn = "0952-7915",